Department of Hematology, Hemotherapy and Cell Therapy, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
Statistical of Department of Hematology, Hemotherapy and Cell Therapy, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazil.
Ann Hematol. 2019 Sep;98(9):2097-2102. doi: 10.1007/s00277-019-03731-w. Epub 2019 Jun 26.
Nodal peripheral T cell lymphomas (nPTCL) present aggressive clinical course, and its heterogeneous nature and poor prognosis with current therapeutic strategies make it a target for the development of new prognostic markers. Thus, we investigated tumor-associated macrophages (TAM) according to the number of cells expressing CD68 in biopsies and the absolute monocyte count (AMC) in peripheral blood of 87 patients with nPTCL. The median overall survival (OS) was 3 years (95% CI 1.3-8.4 years) and estimate 5 years OS of 43.3% (95% CI 32.5-53.7%). The median progression-free survival (PFS) was 1.5 years (95% CI 0.8-2.6 years) with estimate 5 years PFS of 29.2% (95% CI 19.7-39.3%). The cutoff for AMC was 1.5 × 10/L and the median OS for patients with AMC ≥ 1.5 × 10/L was 0.83 years versus 3.7 years for those with AMC < 1.5 × 10/L (HR 2.32, 95% CI 1.03-5.22, p = 0.035). The median PFS for patients with AMC ≥ 1.5 × 10/L was 0.50 years versus 1.5 years for those with AMC < 1.5 × 10/L (HR 2.25, 95% CI 1.05-4.78, p = 0.031). CD68 was evaluated in 26/87 (29.8%) patients with a median expression of 34% and positivity cutoff of 43%. CD68 expression was not associated with OS or PFS either with AMC values. Our findings suggest that the AMC of ≥ 1.5 × 10/L at diagnosis in peripheral blood is associated with poor prognosis in nPTCL. Further investigations in a larger cohort are required to better validate our results.
结外 T 细胞淋巴瘤（nPTCL）表现出侵袭性的临床病程，其异质性和当前治疗策略的不良预后使得其成为新预后标志物的开发目标。因此，我们根据 87 例 nPTCL 患者活检中表达 CD68 的细胞数量和外周血中绝对单核细胞计数（AMC）来研究肿瘤相关巨噬细胞（TAM）。中位总生存期（OS）为 3 年（95%CI 1.3-8.4 年），估计 5 年 OS 为 43.3%（95%CI 32.5-53.7%）。中位无进展生存期（PFS）为 1.5 年（95%CI 0.8-2.6 年），估计 5 年 PFS 为 29.2%（95%CI 19.7-39.3%）。AMC 的截止值为 1.5×10/L，AMC≥1.5×10/L 的患者中位 OS 为 0.83 年，而 AMC＜1.5×10/L 的患者中位 OS 为 3.7 年（HR 2.32，95%CI 1.03-5.22，p=0.035）。AMC≥1.5×10/L 的患者中位 PFS 为 0.50 年，而 AMC＜1.5×10/L 的患者中位 PFS 为 1.5 年（HR 2.25，95%CI 1.05-4.78，p=0.031）。在 87 例患者中的 26 例（29.8%）评估了 CD68，中位表达率为 34%，阳性截断值为 43%。无论 AMC 值如何，CD68 表达与 OS 或 PFS 均无关。我们的研究结果表明，nPTCL 患者外周血中诊断时的 AMC≥1.5×10/L 与不良预后相关。需要在更大的队列中进行进一步研究以更好地验证我们的结果。
